anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Secondary aortoenteric fistula is a rare and life-threatening condition. Clear evidence on the ideal therapeutic approach is largely missing. This study aims to analyze symptoms, etiology, risk factors, and outcomes based on procedural details.
PATIENTS AND METHODS: All patients with secondary aortoenteric fistula admitted between 2003 and 2021 were included. Patient characteristics, surgical procedure details, and postoperative outcomes were analyzed. Outcomes were stratified and compared according to the urgency of operation and the procedure performed. Descriptive statistics were used. The primary endpoint was in-hospital mortality.
RESULTS: A total of twentytwo patients (68% male, median age 70 years) were identified. Main symptoms were gastrointestinal bleeding, pain, and fever. From the twentytwo patients ten patients required emergency surgery and ten urgent surgery. Emergency patients were older on average (74 vs 63 years, P = .015) and had a higher risk of postoperative respiratory complications (80% vs 10%, P = .005). Primary open surgery with direct replacement of the aorta or an extra-anatomic bypass with an additional direct suture or resection of the involved bowel was performed in sixteen patients. In four patients underwent endovascular bridging treatment with the definitive approach as a second step. Other two patients died without operation (1x refusal; 1x palliative cancer history). In-hospital mortality was 27%, respectively. Compared to patients undergoing urgent surgery, those treated emergently showed significantly higher in-hospital (50% vs 0%, P = .0033) mortalities.
CONCLUSION: Despite rapid diagnosis and treatment, secondary aortoenteric fistula remains a life-threatening condition with 27% in-hospital mortality, significantly increased upon emergency presentation.
The VR intervention program for the experimental group will be carried through the Oculus Quest 2 device (which consists of VR glasses and different accessories) will be used, in conjunction with software specifically designed for physical rehabilitation of upper and lower limbs: Dynamics VR. This VR intervention will be performed in addition to the patient's usual treatment program.
PURPOSE:To provide a novel compound which is useful as an antidiabetic and antiobesity agent because it has marked sucrase inhibition activity. CONSTITUTION:The compound of formula I. The compound is obtained by hydrolysis of the compound of formula II in an aqueous solution using a variety of inorganic acids such as hydrochloric acid or sulfuric acid or organic acids such as acetic acid or propionic acid at room temperature to 120 deg.C. The compound of formula I is characterized by that: color and description: basic white powder; solubility: soluble in water, insoluble in acetone, chloroform; molecular formula: C7H12N2O5; molecular weight: 204; specific rotation: [alpha]D<25>+10.0 deg. (C=0.51 in water). The synthetic intermediate for the compound of formula I, trehazoline, is obtained by culturing a strain in Micromonospora, for example, Micromonospora sp. SANK 62390 strain (FERM No.11631).
PURPOSE:To obtain a functional food material, composed of at least either of a lipid fraction in royal jelly and a glyceride of the lipid faction, excellent in preservation stability in a state mixed with a daily ingested food, ingestible together with a food in a natural state and capable of exhibiting pharmacological action. CONSTITUTION:The aforementioned functional food material composed of at least either of a lipid fraction in royal jelly and a glyceride of the lipid fraction. The raw material royal jelly may be either of raw and processed royal jelly and the production area is not limited. The royal jelly is treated with an organic solvent such as ethanol, chloroform or hexane or the organic solvent mixed with water to extract a fraction rich in lipids. The obtained extract solution is directly used or concentrated to a suitable concentration. The aforementioned glyceride is obtained by preparing the above-mentioned concentrate or purified concentrate so as to provide 0.005-20% moisture content and reacting a lipase therewith.
The participants in group 1 will receive AA as an adjunctive therapy to TaU (i.e. individual counseling therapy, psycho therapy, pharmacological therapy) during 8 weeks.
Patients randomized to the Standard Therapy arm will not undergo genotyping. All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
A method of inhibiting COX-2, inhibiting NF-Kappa B activation, treating inflammation, or treating cancer may comprise administering a therapeutically effective amount of an extract of Combretum laurifolium Mart. to a patient. A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Combretum laurifolium Mart. suspended in the vehicle. A method of making an extract of Combretum laurifolium Mart. may comprise creating a component solution by treating Combretum laurifolium Mart. material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution. An extract of Combretum laurifolium Mart. may comprise components extracted using various solvents.
BACKGROUND AND OBJECTIVE: Understanding the regulation of efferocytosis by myeloid phagocytes is important in identifying novel targets in systemic lupus erythematosus (SLE). Cadherin-11 (CDH11), a cell adhesion molecule, is implicated in inflammatory arthritis and fibrosis and recently been shown to regulate macrophage phagocytosis. The extent and mechanism of this regulation is unknown. Our objective was to examine the extent to which CDH11 regulates myeloid phagocytes and contributes to autoimmunity and tissue inflammation.
METHODS: We analyzed efferocytosis in macrophages and dendritic cells (DCs) from WT and Cdh11-/- mice and investigated the mechanisms in vitro. We investigated the role of CDH11 in disease development in vivo using the pristane induced lupus model. To translate the clinical relevance of CDH11 in human disease, we measured serum CDH11 levels in two independent pediatric SLE (pSLE) cohorts and healthy controls.
RESULTS: Using bone marrow derived macrophages (BMDMs) and DCs (BMDCs), we found impaired efferocytosis in phagocytes from Cdh11-/- mice, mediated by downregulated efferocytosis receptor expression and RhoGTPase activation. Specifically, loss of CDH11 downregulated Mertk expression and Rac1 activation in BMDMs, and integrin αVβ3 expression and Cdc42 activation in BMDCs, highlighting distinct pathways. In vivo, Cdh11-/- mice displayed defective efferocytosis and increased accumulation of apoptotic debris in pristane-induced lupus. Further, Cdh11-/- mice had enhanced systemic inflammation and autoimmune inflammation with increased anti-dsDNA autoantibodies, splenomegaly, type I interferons, and inflammatory cytokines. Paradoxically, at the tissue level, Cdh11-/- mice were protected against glomerulonephritis, indicating a dual role in murine lupus. Finally, SLE patients had increased serum CDH11 compared to controls.
CONCLUSION: This study highlights a novel role of CDH11 in regulating myeloid cells and efferocytosis and its potential as a contributor to development in autoimmunity murine lupus. Despite the increase in autoimmunity, Cdh11-/- mice developed decreased tissue inflammation and damage.
Plant pathogens are constantly under selection pressure for host resistance adaptation. Soybean cyst nematode (SCN, Heterodera glycines) is a major pest of soybean primarily managed through resistant cultivars; however, SCN populations have evolved virulence in response to selection pressures driven by repeated monoculture of the same genetic resistance. Resistance to SCN is mediated by multiple epistatic interactions between Rhg (for resistance to H. glycines) genes. However, the identity of SCN virulence genes that confer the ability to overcome resistance remains unknown. To identify candidate genomic regions showing signatures of selection for increased virulence, we conducted whole genome resequencing of pooled individuals (Pool-Seq) from two pairs of SCN populations adapted on soybeans with Peking-type (rhg1-a, rhg2, and Rhg4) resistance. Population differentiation and principal component analysis-based approaches identified approximately 0.72-0.79 million SNPs, the frequency of which showed potential selection signatures across multiple genomic regions. Chromosomes 3 and 6 between population pairs showed the greatest density of outlier SNPs with high population differentiation. Conducting multiple outlier detection tests to identify overlapping SNPs resulted in a total of 966 significantly differentiated SNPs, of which 285 exon SNPs were mapped to 97 genes. Of these, six genes encoded members of known stylet-secreted effector protein families potentially involved in host defence modulation including venom-allergen-like, annexin, glutathione synthetase, SPRYSEC, chitinase, and CLE effector proteins. Further functional analysis of identified candidate genes will provide new insights into the genetic mechanisms by which SCN overcomes soybean resistance and inform the development of molecular markers for rapidly screening the virulence profile of an SCN-infested field.
As with all therapeutic proteins, there is potential for immunogenicity with SILIQ. Approximately 3% of subjects treated with SILIQ developed antibodies to brodalumab through the 52-week treatment period. Of the subjects who developed antibodies to brodalumab, none had antibodies that were classified as neutralizing. However, the assay to test for neutralizing antibodies had limitations detecting neutralizing antibodies in the presence of brodalumab; therefore, the incidence of neutralizing antibody development could be underestimated.

The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to SILIQ with the incidence of antibodies to other products may be misleading.
AIMS: Embolic stroke of undetermined source (ESUS) results in significant morbidity. A left atrial (LA) myopathy is implicated in a proportion of these patients. We hypothesized that LA shape varies by cause of stroke [CE (cardioembolic) vs. ESUS].
METHODS AND RESULTS: A total of 236 ischaemic stroke and atrial fibrillation (AF) patients and controls were recruited prospectively. AF was classified as paroxysmal AF (PAF) or persistent AF (PersAF). Stroke patients comprised CE stroke secondary to AF and ESUS. There were 81 AF (47 PAF, 34 PersAF), 50 ESUS, 57 CE patients [subdivided into CE with PAF (CEpaf) and CE with PersAF (CEpers)], and 48 controls. Echocardiographic parameters including LA volume, function, and shape/sphericity (3D LA sphericity and 2D-derived LA circularity, ellipticity, sphericity, and eccentricity indices) were evaluated. Increased LA volume and sphericity with LA dysfunction were present in CE, AF, and ESUS groups compared with controls. K-means cluster analysis demonstrated a spectrum of LA myopathy with controls at the lowest and CEpers and PersAF at the upper extremes, with ESUS, PAF, and CEpaf being similar and falling between these extremes. After adjusting for age, sex, and left ventricular (LV) and LA parameters, LA sphericity markers differentiated ESUS from controls (P < 0.01).
CONCLUSION: Alterations in LA shape are present in ESUS, AF, and CE patients, particularly increased spherical remodelling. The novel markers of LA sphericity proposed may identify LA myopathy in ESUS patients and potentially guide management for secondary prevention.
INTRODUCTION: Focused assessment with sonography for trauma helps detect abdominal free fluid. Prehospital ultrasound scanning is also important because the early diagnosis of hemoperitoneum may reduce the time to definitive treatment in the hospital. This study investigated whether prehospital ultrasound scanning can help detect abdominal free fluid.
MATERIALS AND METHODS: In this systematic review, relevant databases were searched for studies investigating prehospital ultrasound examinations for abdominal free fluid in trauma patients. The prehospital ultrasound results were compared with computed tomography, surgery, or hospital ultrasound examination data. The pooled sensitivity and specificity values were analyzed using forest plots. The overall predictive power was calculated by the summary receiver operating characteristic curve. The quality of the included studies was assessed using the quality assessment of diagnostic accuracy studies tool. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) was performed to assess the certainty of evidence.
RESULT: This meta-analysis comprised six studies that included 1356 patients. The pooled sensitivity and specificity values were 0.596 (95% confidence interval [CI] = 0.345-0.822) and 0.970 (95% CI = 0.953-0.983), respectively. The pooled area under the summary receiver operating characteristic curve was 0.998. The quality assessment tool showed favorable results. In the GRADE analysis, the quality of evidence was very low for sensitivity and high for specificity when prehospital ultrasound was used for hemoperitoneum diagnosis.
CONCLUSION: The specificity of abdominal free fluid detection using prehospital ultrasound examinations in trauma patients was very high.
The invention discloses application of a small molecule inhibitor ML385 in inhibiting tumor cells PD-L1. Further, the ML385 inhibitor can inhibit the function of PD-L1 in tumor cells and activate the anti-tumor immune function of T cells. The embodiment of the invention also provides application of a small molecule inhibitor ML385 in inhibiting tumor cells PD-L1 and PD-L2. Further, the ML385 inhibitor inhibits the expression of PD-L1 and PD-L2 by inhibiting the binding of NRF2 and MAF, disrupting the core site where NRF2 recognizes PD-L1L 2-SE. The embodiment of the invention also provides a medicament for killing tumor cells, which is characterized by comprising a small molecule inhibitor ML 385. Further, the medicament also comprises an anti-PD-L1 antibody or an anti-PD-L2 antibody. Experiments in the examples of the invention prove that in breast cancer cells SUM159 and MDA-MB-231, the expression of PDL1 is obviously inhibited by the small molecule inhibitor ML 385.
Trichotillomania (TTM) is a disorder in which people compulsively pull out their own hair. Treatments for TTM sometimes do not have long-term effectiveness. Acceptance and commitment therapy (ACT) is a therapeutic approach thought to have longer lasting effects than standard cognitive behavioral therapy (CBT) approaches, because ACT focuses on accepting thoughts and behaviors as opposed to changing them. Previous research indicates that a combination of ACT and habit reversal behavioral therapy is more effective than no treatment. This study will test whether a combination of ACT and behavioral therapy, called acceptance enhanced behavioral therapy (AEBT), is more effective than the current standard treatment for TTM.

Participation in this study will last 12 weeks, and follow-up assessments will last for 6 months. At study entry, participants will complete a brief intelligence test and an in-person interview about their medical history, psychiatric history, and hair pulling. At their second visit, participants will have digital pictures taken of their hair-pulling sites and complete two computer tasks measuring their response inhibition and cognitive flexibility. After the second visit, participants will be randomly assigned to receive either AEBT or psychoeducation and supportive therapy (PST)-a standard treatment for TTM. Both treatments will involve ten 1-hour sessions completed over 12 weeks. Assessments of participants will occur after 6 weeks of treatment, at treatment completion, and after 6 months. These assessments will measure treatment effectiveness, based on several clinical scales and measures of TTM symptoms. Participants who receive PST during this study will be offered AEBT afterward.
The invention provides a peptide, a nucleotide sequence coding the peptide, a pharmaceutical composition containing the peptide, and pharmaceutical purpose of the peptide. An amino acid sequence of the peptide provided by the invention is as shown in SEQ. ID. NO. 1. The peptide can interfere combination of MLK3 with PSD-95, inhibit activation of the MLK3 and cellular signal transduction at the downstream of the MLK3 during a neuronal apoptosis process, thereby resulting in neuroprotection and having a good medicament application prospect.
The present invention relates to a medicated pillow (trivial name of Gantai medicated pillow) and a preparation method thereof. The medicated pillow is used for treating influenza, rhinitis, headache, vertigo, hypertension, etc. The medicated pillow is prepared by crushing 15 medicines into coarse powder and packaging the coarse powder with a piece of cloth with good air permeability. By adopting the scheme, the effective rate for treating diseases is 100%, and the cure rate is higher than 95%. The selected medicines are easy to obtain; the treatment fee is low; patients feel no pain. The medicated pillow is ideal for people to prevent and treat diseases.
PURPOSE: Locoregionally advanced HPV+ oropharyngeal squamous cell carcinoma (OPSCC) has excellent cure rates, although current treatment regimens are accompanied by acute and long-term toxicities. We designed a phase II deescalation trial for patients with HPV+ OPSCC to evaluate the feasibility of an upfront neck dissection to individualize definitive treatment selection to improve the quality of life without compromising survival.
PATIENTS AND METHODS: Patients with T1-3, N0-2 HPV+ OPSCC underwent an upfront neck dissection with primary tumor biopsy. Arm A included patients with a single lymph node less than six centimeters, with no extracapsular spread (ECS) and no primary site adverse features underwent transoral surgery. Arm B included patients who had two or more positive lymph nodes with no ECS, or those with primary site adverse features were treated with radiation alone. Arm C included patients who had ECS in any lymph node and were treated with chemoradiation. The primary endpoint was quality of life at 1 year compared with a matched historical control.
RESULTS: Thirty-four patients were enrolled and underwent selective neck dissection. On the basis of pathologic characteristics, 14 patients were assigned to arm A, 10 patients to arm B, and 9 to arm C. A significant improvement was observed in Head and Neck Quality of Life (HNQOL) compared with historical controls (-2.6 vs. -11.9, P = 0.034). With a median follow-up of 37 months, the 3-year overall survival was 100% and estimated 3-year estimated progression-free survival was 96% [95% confidence interval (CI), 76%-99%].
CONCLUSIONS: A neck dissection-driven treatment paradigm warrants further research as a deintensification strategy.
<P>PROBLEM TO BE SOLVED: To provide a liver protecting test, immunity test, and safety test using antrodia camphorata.  <P>SOLUTION: A rat and mouse are medicated with an antrodia camphorata capsule. First, in a liver protecting test, two times every week, for a total of eight weeks, a morbidity rat of chronic hepatitis induced by carbon tetrachloride is used, and measurement of GPT and GOT, measurement of weight of a liver and spleen, and liver water content, measurement of a liver protein and hydroxyproline content are carried out. In a specific immunity test, a BALB/c mouse is medicated with a test substance, and is injected with egg albumin, then the immunity regulation function of an immunity cell growth action and serum specific antibody preparation are measured. In a nonspecific immunity test, continuation of six weeks, the administration test of the test substance to BALB/c mouse is performed, the promotion of peritoneal macrophage activity, the regulating of hormonal secretion of an antitumor cell, and the immunity regulation function which promotes serum antibody preparation are measured. In any test, antrodia camphorata extract has shown effectiveness.  <P>COPYRIGHT: (C)2011,JPO&INPIT
By subcutaneous injection of a solution with a concentration of 125 mg/mL placebo in a supine position: Patients in Xolair (Immunoglobulin E (IgE) = 30-300 IU/mL) group received doses of 150 mg to 375 mg of placebo every 2 or 4 weeks for 12 or 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 700- 2000 IU/mL) group received doses of 450 mg, 525 mg, or 600 mg of placebo every 2 weeks for 14 weeks. Patients in Xolair (Immunoglobulin E (IgE) = 301- 699 IU/mL) group received doses of 225 mg to 375 mg of placebo every 2 weeks for 6 weeks.
Phase I treatment is 8 weekly sessions of cognitive behavioral therapy (CBT). At the 10-week follow-up participants who are non-responders to Phase I CBT will switch to 8 weekly sessions of mindfulness using a mindfulness-oriented recovery enhancement protocol as Phase II treatment. If participant is a responder to Phase I CBT, he or she will receive up to 2 more CBT sessions in Phase II of treatment.
A composition having enhanced skin protection properties against ultraviolet rays comprises at least one sunscreen composition and at least one polysaccharide alkylether comprising at least two different moieties and at least one hydroxyl group substituted with a saturated C 1 -C 24  alkyl chain. A method for enhancing the skin protection properties against ultraviolet rays of sunscreen compositions comprises applying to the skin a composition comprising at least one sunscreen composition and at least one polysaccharide alkylether comprising at least two different moieties and at least one hydroxyl group substituted with a saturated C 1 -C 24  alkyl chain. A composition for extending the longevity of fragrance on the skin comprises at least one fragrance composition and at least one polysaccharide alkylether comprising at least two different moieties and at least one hydroxyl group substituted with a saturated C 1 -C 24  alkyl chain. A method for extending the longevity of fragrance on the skin comprises applying to the skin a composition comprising at least one fragrance composition and at least one polysaccharide alkylether comprising at least two different moieties and at least one hydroxyl group substituted with a saturated C 1 -C 24  alkyl chain. An anhydrous composition for delivering one or more vitamins to the skin comprises at least one vitamin and at least one polysaccharide alkylether comprising at least two different moieties and at least one hydroxyl group substituted with a saturated C 1 -C 24  alkyl chain. A method for delivering one or more vitamins to the skin comprises applying to the skin a composition comprising at least one vitamin and at least one polysaccharide alkylether comprising at least two different moieties and at least one hydroxyl group substituted with a saturated C 1 -C 24  alkyl chain.